• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Global 500

Alphabet and Sanofi Set Up a Joint Venture in Diabetes Treatment

By
Reuters
Reuters
and
Michelle Toh
Michelle Toh
By
Reuters
Reuters
and
Michelle Toh
Michelle Toh
September 12, 2016, 1:23 AM ET
A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris
A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann/File PhotoPhotograph by Christian Hartmann—Reuters

French drugmaker Sanofi (SNYNF) and Google (GOOG) owner Alphabet’s U.S-based life sciences company Verily, announced on Monday the launch of a joint-venture aimed at offering patients suffering from diabetes products that will combine devices and services.

Sanofi said last year it was working on a partnership with Google in diabetes.

“The company will leverage Verily’s (formerly Google Life Sciences) experience in miniaturized electronics, analytics, and consumer software development, and Sanofi’s clinical expertise and experience in bringing innovative treatments to people living with diabetes,” the two companies said on Monday.

Nearly 400 million people worldwide have diabetes, with the type 2 version accounting for more than 90% of cases. Without proper treatment or lifestyle changes, those numbers are expected to grow substantially in the coming years.

Get Term Sheet, Coins2Day’s daily email about deals and deal-makers.

The JV, called Onduo, “will initially focus on the type 2 diabetes community, specifically on developing solutions that could help people make better decisions about their day to day health, ranging from improved medication management to improved habits and goals,” Sanofi and Verily said.

A spokeswoman for Sanofi said products on sale would include connected objects such as insulin pens and online services.

See also: Sanofi Is Shuffling Its Exec Roster Amid Continued Struggles

No financial details were disclosed but the spokeswoman said Sanofi had invested $248 million in the joint venture, in which the French group controls a 50% stake.

The group is actively working at reviving declining sales in its diabetes division, hurt by sustained pricing pressure in the United States, the world’s largest health market.

About the Authors
By Reuters
See full bioRight Arrow Button Icon
By Michelle Toh
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.